502649-25-4

Basic information

• Product Name: N-1-Boc-3-phenylpiperazine
• Synonyms: 3-PHENYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;3-PHENYLPIPERAZINE, N1-BOC PROTECTED;TERT-BUTYL 3-PHENYLPIPERAZINE-1-CARBOXYLATE;N-1-BOC-3-PHENYL PIPERAZINE;N-1-BOC-3-PHENYL PIPERIZINE;1-N-Boc-3-phenylpiperizine;1-N-Boc-3-Phenylpiperazine;N-BOC-3-PHENYLPIPERAZINE
• CAS NO: 502649-25-4
• Molecular Formula: C₁₅H₂₂N₂O₂
• Molecular Weight: 262.35
• Product Categories: Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 502649-25-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 371.4 °C at 760 mmHg
• Flash Point: 178.4 °C
• Appearance: /
• Density: 1.071 g/cm³
• Vapor Pressure: 1.03E-05mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.70±0.40(Predicted)
• CAS DataBase Reference: N-1-Boc-3-phenylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: N-1-Boc-3-phenylpiperazine(502649-25-4)
• EPA Substance Registry System: N-1-Boc-3-phenylpiperazine(502649-25-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 502649-25-4(Hazardous Substances Data)

Usage

Description

N-1-Boc-3-phenylpiperazine, also known as tert-Butyl 3-phenylpiperazine-1-carboxylate, is an organic compound that serves as a crucial building block in the synthesis of various pharmaceutical compounds. It is characterized by its piperazine and phenyl groups, which contribute to its reactivity and potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Research:
N-1-Boc-3-phenylpiperazine is used as a research reagent for the preparation of piperazinylphenyl pyrrolotriazinamines. These compounds are known as PI3Kδ inhibitors, which play a significant role in the development and progression of various diseases, including cancer and autoimmune disorders. The inhibition of PI3Kδ has been shown to have therapeutic potential in these conditions, making N-1-Boc-3-phenylpiperazine a valuable tool in the development of novel treatments.

InChI:InChI=1/C15H22N2O2/c1-15(2,3)19-14(18)17-10-9-16-13(11-17)12-7-5-4-6-8-12/h4-8,13,16H,9-11H2,1-3H3

Upstream product

• 1074-12-0 phenylglyoxal hydrate 
• 29460-97-7 2-phenylpyrazine 
• 5271-26-1 m-phenylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1203590-31-1 4-benzyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1598383-11-9 4-methyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists

The P2X7 receptor (P2X7R) stands out among the purinergic receptors due to its strong involvement in the regulation of tumor growth and metastasis formation as well as in innate immune responses and afferent signal transmission. Numerous studies have pointed out the beneficial effects of P2X7R antagonism for the treatment of a variety of cancer types, inflammatory diseases, and chronic pain. Herein we describe the development of novel P2X7R antagonists, incorporating piperazine squaric diamides as a central element. Besides improving the antagonists’ potency from pIC50 values of 5.7–7.6, ADME properties (logD7.4 value, plasma protein binding, in vitro metabolic stability) of the generated compounds were investigated and optimized to provide novel P2X7R antagonists with drug-like properties. Furthermore, docking studies revealed the antagonists binding to the allosteric binding pocket in two distinct binding poses, depending on the substitution of the central piperazine moiety.

PIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS WITH INCREASED THERAPEUTIC ACTIVITY

The present invention provides 2-phenylpiperazine derivatives having a benzofuran-2-yl group which contributes to increase the antiviral activity as well as, for some substituents, the CC50, giving more active and less cytotoxic compounds. Alth

Piperazine derivatives and the use thereof as medicament

The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).